RDPAC’s Joseph Cho On Reimbursement In China And Regulatory Reform: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
With China’s updated Essential Drugs List expected any day, PharmAsia News sat down with the head of the Big Pharma trade group in China to discuss the impact.
You may also be interested in...
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.